Kornimate/medical-research-clean huggingface dataset:
effectiveness of manual manipulation with epat on ankle dorsiflexion and dynamic plantar pressure

Conditions: Diabetes; Equinus Contracture of the Ankle

Summary: diabetic foot complications are a common and costly problem. excessive plantar pressures due to foot deformities and/or limited ankle dorsiflexion, especially in the presence of peripheral neuropathy, can predispose subjects with diabetes for diabetic foot ulcers. achilles tendon lengthening surgery has shown to delay or prevent recurrence of diabetic foot ulcers. studies have shown that shockwave therapy (epat - extracorporeal pulse activation technology) was effective in treating subjects with chronic heel pain and achilles tendonitis with no serious side effects. epat, therefore, may allow diabetic patients with ankle equinus to perform more effective stretching exercises and may prevent recurrence of diabetic foot ulcers. the purposed of this rct is to compare effectiveness of manual manipulation with epat versus manual manipulation alone on ankle dorsiflexion and dynamic plantar pressure in at-risk subjects with a history of diabetic foot ulcer.


Eligibility criteria:
inclusion criteria: * men and women between the ages of 21 to 65, inclusive * diabetes, either type 1 or 2 * ankle equinus (\< 0º passive ankle dorsiflexion with knee extended) * forefoot plantar hyperkeratosis (callus) * able to walk independently without the use of walking aids (cane, crutches, or walker) * able to understand the information in the informed consent form and willing and able to comply with study-related procedures exclusion criteria: * previous history of ankle-foot surgery or amputation * no active lower extremity skin ulcers * peripheral vascular disease (non-palpable pedal pulses or ankle brachial index \<0.8) * not willing or able to make required visits * nursing or pregnant * not willing or able to follow procedures specified by protocol and/or instructions of the study personnel, including discontinuation of icing, nsaids and natural anti-inflammatory agents (such as arnica)

Keywords: diabetes ankle equinus ankle dorsiflexion dynamic plantar pressure shockwave therapy
active and passive distraction in children undergoing wound dressings

Conditions: Minor Trauma

Summary: the hypothesis was that an active distraction is more effective than a passive distraction in conjunction with procedural pain in children. the specific aim in this study was to test how an active distraction, serious gaming and a passive distraction, the use of lollipops influence pain, distress and anxiety in children during wound care.


Eligibility criteria:
inclusion criteria: children aged five to twelve were recruited from the pediatric day care unit at the queen silvia children's hospital, gothenburg, sweden. included children had wounds that differed in size and location but were too extensive to be handled in a primary care setting. the wound dressing procedures were standardized and the pain experiences were expected to be similar in all included children. exclusion criteria: children with longstanding wounds, care-related pressure wounds, and wounds in body areas with decreased sensitivity were excluded from this study.children with cognitive impairments were excluded from the study, as were children or parents who did not have a good command of swedish.
study of sta-5326 mesylate in patients with moderate to severe crohn's disease

Conditions: Crohn's Disease

Summary: sta-5326 is an experimental drug that has been shown to block the release of interleukin-12 from peripheral blood mononuclear cells. given this activity on the immune system, sta-5326 mesylate is a potential treatment for various autoimmune diseases, such as crohn's disease, that are mediated by the inappropriate expression of th1 cytokines. this study is evaluating the use of sta-5326 mesylate in patients with moderate to severe, active crohn's disease. study visits include a screening visit, 9 treatment period visits over 6 months and a follow-up visit that will occur 30 days following the end of treatment. study drug treatment will continue for up to 6 months.


Eligibility criteria:
inclusion criteria: * is male or female aged 18 through 75 years. * has crohn's disease diagnosed definitively prior to screening (based upon clinical, endoscopic, radiologic imaging, or histological assessments). * has a crohn's disease activity index (cdai) score of 220 to 450, inclusive at baseline. exclusion criteria: * has any clinically significant disease (eg, renal, hepatic, neurological, cardiovascular, pulmonary, endocrinologic, psychiatric, hematologic, urologic, or other acute or chronic illness) that, in the opinion of the investigator, would make the patient an unsuitable candidate for this study. * is a woman who has a positive pregnancy test, who is breast-feeding, or who is sexually active without using birth control during the course of the study and follow-up period. * is a woman of childbearing potential or a man who does not agree to use 2 forms of contraception during the course of the study and follow-up period. * has clinically significant hematologic, hepatic or renal laboratory abnormalities.

Keywords: crohn's disease gastroenterology
experimental study of strength training to activate the quadriceps muscle after total knee arthroplasty

Conditions: Osteoarthritis, Knee

Summary: background: progressive strength training is a training modality used in rehabilitation after total knee arthroplasty (tka). strength deficits up to 80% in the quadriceps muscle is shown to be present in the operated leg after tka, which relates to reduced central nervous system (cns) activation of the muscle. as increased cns activation occurs during strength training when muscular fatigue is approaching in healthy subjects, it is relevant to investigate if this also is the case after tka. the clinical implication is that repetitions performed to contraction failure during strength training, may help reduce cns activation deficits of the quadriceps muscle after tka. purpose: the aim of this study is to investigate cns activation of the quadriceps muscle during strength training performed with repetitions to contraction failure after tka. method: electromyographic (emg) activity of the vastus medialis (vm), vastus lateralis (vl), semitendinosus (st) and biceps femoris (bf) muscles will be recorded during knee extensions performed in a knee extension machine until contraction failure. the relative loading will be 10 repetition maximum (rm). the absolute load (kilograms) corresponding to 10 rm is defined a minimum of 3 days before the day where the emg-data are recorded. the primary outcomes will be normalized emg amplitude and median power frequency for each 10th (10%, 20%, 30% failure, etc.) of the set to failure. hypothesis: based on previous findings in healthy subjects, we hypothesize that in patients with a tka, the emg amplitude will increase while the median power frequency will decrease during a strength training set performed to contraction failure after tka.


Eligibility criteria:
inclusion criteria: * unilateral primary tka * between the age of 18 to 80 years * understand and speak danish * informed consent * 4 to 8 weeks after tka exclusion criteria: * disease/musculoskeletal disorder, which requires special rehabilitation modality * alcohol and drug abuse * lack of wish to participate or unwillingness to sign an informed consent

Keywords: strength training resistance training fatigue knee extension total knee arthroplasty total knee replacement electromyography physical therapy modalities
delayed language development in children with cleft palate at sohag university hospital

Conditions: Delayed Language in Cleft Palate

Summary: this is a retrospective study on children with cleft palate who came to the multidisciplinary cleft clinic at sohag university hospital from september 2017 to september 2023


Eligibility criteria:
inclusion criteria: * cleft palate children's exclusion criteria: * cleft lip only
safety and clinical and virologic outcomes in ckd patients treated with nirmatrelvir-ritonavir

Conditions: COVID-19; Chronic Kidney Disease stage4; Chronc Kidney Disease Stage 5

Summary: nirmatrelvir-ritonavir is approved for coronavirus disease 2019 (covid-19) but not initially recommended in patients with severe renal impairment. increasing observational data have shown the feasibility of dose-adjusted nirmatrelvir-ritonavir administration in patients with estimated glomerular filtration rate lower than 30 ml/min/1.73 m\^2. the study is planned to assess the safety, clinical and virologic outcomes of early oral nirmatrevir-ritonavir treatment of covid-19 in patients with stage 4 and 5 chronic kidney disease.

the objectives of the study are to evaluate the safety and clinical and virologic outcomes of dose-adjusted nirmatrelvir-ritonavir in patients with egfr lower than 30 ml/min/1.73 m\^2. patients with egfr greater than 30 ml/min/1.73 m2 and prescribed nirmatrelvir-ritonavir will be used for comparison. in the single-centre study, patients with stage 4 and 5 chronic kidney disease prescribed early treatment dose-adjusted nirmatrelvir-ritonavir will be assessed for the primary endponts of adverse events during or after treatment with nirmatrelvir-ritonavir (starting on or before day 30), serious adverse events and adverse events leading to discontinuation of nirmatrelvir-ritonavir.

Eligibility criteria:
inclusion criteria: * aged 18 and above. * covid-19 infection and symptom onset no more than 5 days, with or without prior vaccination. * who cps 1-4 * indicated for nirmatrelvir-ritonavir treatment exclusion criteria: * patients cannot swallow capsules or adhere to protocol. * severe covid-19 disease, including patients who require oxygen supplement therapy * significant hypersensitivity to nirmatrelvir, ritonavir, or any component of the formulation * patients require co-administration of drugs that are highly dependent on cyp3a4 for clearance and cannot be omitted during the treatment period
incidence of descemet membrane detachment post gatt by as oct

Conditions: Angle Glaucoma Open

Summary: detection of incidence of descemet membrane detachment post gonioscopy-assisted transluminal trabeculotomy by anterior segment optical coherence tomography in patients with open angle glaucoma.

in our study, which should include 30 eyes with oag who underwent 360 gatt screening for descemet membrane detachment will be done by anterior segment optical coherence tomography using sd-oct: optovue rtvue (optovue inc., fremont, ca, usa) for the angle day 1 post operative for all patients and 1 week post operative in cases with descemet membrane detachment to check for spontaneous resolution. one month post-operative the patients underwent * best corrected visual acuity (bcva) using decimal. * iop measurement using gat.

Eligibility criteria:
inclusion criteria: 1. age 18 - 70 years. 2. patients with open angle glaucoma undergoing gonioscopy assisted transluminal trabeculotomy. exclusion criteria: 1. patients with with open angle glaucoma and aphakia. 2. patients with congenital glaucoma. 3. patients with open angle glaucoma undergoing phaco -gonioscopy-assisted transluminal trabeculotomy. 4. patients with neovascular glaucoma. 5. patients with pigmentary glaucoma.

Keywords: gonioscopy-assisted transluminal trabeculotomy descemet membrane detachment
genetic studies in liver cancer patients

Conditions: Hepatocellular Carcinoma

Summary: hepatocellular carcinoma (hcc) is one the most common malignancies in the world, especially in sub-saharan africa and southeast asia. since 1984, it has been the leading cause of cancer death in taiwan. about 6000-8000 people died of this cancer every year in taiwan. dna microarray (dna chip) is a very powerful tool to clarify the genetic changes in cancers. expression profiling techniques have been used to simultaneously monitor the expression of thousands of genes from human tumor samples. it has been successfully used to predict clinical outcome and survival as well as classify different types of cancer. in this study, we will use the dna chip to study the genetics in liver cancer patients.

the clinical samples will be collected in the ntuh, while the dna microarray works will be done in biomedical engineering center (bmec) of itri. patients a total of 40 cases of hcc patients (20 hbv-related hcc and 20 hcv-related hcc) who received surgical resection in national taiwan university hospital will be enrolled from our tissue banks. the diagnosis of hcc was confirmed by pathological examination. the surgical specimens were frozen immediately after surgery and stored in -140°c. the clinicopathological data will be retrospectively obtained from chart reviews. another total of 40 new hcc patients who receive surgical resection in national taiwan university hospital will be collected. the healthy subjects and patients chronically infected with hbv or hcv without hcc will be used as controls. the whole bloods will be collected before, one and six months after operation. the diagnosis of hcc will be confirmed by pathology. in addition to the whole bloods, the surgical specimens will be frozen immediately after surgery and stored in -140°c.

Eligibility criteria:
inclusion criteria: * hepatocellular carcinoma exclusion criteria: * multiple cancers
effects of intra muscular electrotherapy combined with manipulative therapy in patients with sacral torsion

Conditions: Sacroiliac Joint Dysfunction

Summary: this study is a randomised controlled trial and the purpose of this study is to determine the effect of intra muscular electrotherapy combined with manipulative therapy in terms of pain, mobility, range of motion, and disability."

the purpose of this study is to determine the effect of intra muscular electrotherapy combined with manipulative therapy in terms of pain, mobility, range of motion, and disability in patients with sacral torsion." (age : 22-44 years ) 1. numeric pain rating scale 2. inclinometer lumbar flexion 3. oswestry disability questionairre 4. goniometer slr rom data will be collected before and after the intervention protocol for each participant. data collection procedure: participants of interest would be approached and explained about the research. informed written consent will be taken. pre and post intervention scores will be recorded.

Eligibility criteria:
inclusion criteria: * age group: 22-44 years old * both males and females * clinically diagnosed sacral torsion * patients with pain intensity of at least 5 on nprs * positive backward bent test * positive forward bent test * uneven sacral sulcus * uneven ila of sacrum * piriformis syndrome exclusion criteria : * any congenital deformities * demonstrated neurological deficit. * pregnant females * history of spinal surgery * spondylolisthesis * severe lumbar spondylosis * spinal stenosis * serious spinal conditions like infection, tumors, osteoporosis, spinal fracture * osteoporosis
efficacy, safety and tolerability of everolimus in preventing end-stage renal disease in patients with autosomal dominant polycystic kidney disease

Conditions: Autosomal Dominant Polycystic Kidney Disease

Summary: this study will assess whether everolimus (rad001) is effective in preventing cyst and kidney expansion as well as worsening of renal function in patients with adpkd and whether the application of 5 mg/day everolimus as monotherapy is safe and well tolerated.


Eligibility criteria:
inclusion criteria 1. clinical diagnosis of autosomal dominant polycystic kidney disease adpkd 2. chronic kidney disease (ckd) stage ii / iii 3. females capable of becoming pregnant must have a negative serum pregnancy test within 7 days prior to or at baseline, and are required to practice an approved method of birth control for the duration of the study and for a period of 6 weeks following discontinuation of study medication, even where there has been a history of infertility exclusion criteria 1. adpkd patients with normal renal function 2. adpkd patients with ckd stage iv 3. patients with a history of subarachnoid bleeding 4. patients with a history of severe infections 5. patients with life-threatening urinary tract or cyst infection in the past 6. patients who have received any investigational drug within four weeks prior to baseline 7. patients who have been treated with any non-protocol immunosuppressive drug or treatment within one month prior to baseline other protocol-defined inclusion/exclusion criteria may apply

Keywords: end-stage renal disease, esrd, autosomal dominant polycystic kidney disease, adpkd, everolimus
study of the safety and efficacy of an investigational drug in adult patients with multiple myeloma

Conditions: Multiple Myeloma

Summary: the primary goal of the study is to determine the best dose of an investigational drug to give to patients with multiple myeloma and to evaluate the investigational drug's effectiveness as a treatment for multiple myeloma.


Eligibility criteria:
other specific inclusion/exclusion criteria may apply. in order to determine eligibility, further examination by the investigator is necessary. inclusion criteria: * eligible patients must be at least 18 years of age with a diagnosis of multiple myeloma including elevated m-blood/urine protein or a tumor that can be evaluated by the doctor during the investigational drug's treatment. * the patient's multiple myeloma must have gotten worse during/after previous chemotherapy was given. * any side-effects from prior chemotherapy must have subsided * blood and urine tests must show adequate bone marrow, liver, and kidney function. exclusion criteria: any of the following will exclude patients from study participation: * indolent or smoldering myeloma or localized plasmacytoma * hyperviscosity syndrome * irradiation to 25% or more of bone marrow * prior high dose chemotherapy with bone marrow or stem cell support * current participation in other clinical trials * pregnant or breast-feeding women * known hiv-positive or aids-related illness * patients planning to have radiation therapy or surgery that would interrupt study therapy in the next 6 months.

Keywords: pharmacia
epidemiology of carotid imt progression in mesa - ancillary study

Conditions: Atherosclerosis; Cardiovascular Diseases; Heart Diseases; Carotid Artery Diseases; Coronary Arteriosclerosis

Summary: to determine the factors associated with progression of sub-clinical atherosclerosis and to evaluate the associations between the progression of sub-clinical atherosclerosis and the development of clinically manifest atherosclerosis.

background: cardiovascular disease remains the leading cause of death in the united states and one of the leading causes of morbidity. new technology recently has allowed the non-invasive investigation of the extent of atherosclerosis in different vascular beds. unfortunately, the clinical implications and significance of this new technology have not yet been fully examined nor has the interrelationship between these various measurements of clinical and sub-clinical atherosclerosis. the study is ancillary to the multi-ethnic study of atherosclerosis (mesa), an nhlbi-supported epidemiological study of atherosclerosis in several ethnic groups. design narrative: a longitudinal assessment of the carotid intima media thickness (imt) will be added to the scheduled follow-up visits in mesa subjects in order to study the relationship between carotid imt and a measure of calcium burden in the coronary vessels. in addition, studies will be conducted on how these two non-invasive markers of atherosclerosis relate to cardiovascular disease risk factors and clinical events.the study will utilize the mesa cohort involving 6500 subjects who will have baseline and four follow-up examinations. coronary artery calcification (cac) and imt are being obtained at baseline, with cac determinations also scheduled at follow-up. imt determinations will be added in conjunction with the cac studies in the second and third exams and detailed analyses will be carried out on these two measures of atherosclerotic burden that may reflect different biologic processes.

Eligibility criteria:
members of mesa study
allogeneic bone marrow transplant for inherited metabolic disorders

Conditions: Mucopolysaccharidosis; Hurler Syndrome; Hunter Syndrome; Maroteaux-Lamy Syndrome; Sly Syndrome; Alpha Mannosidosis; Fucosidosis; Aspartylglucosaminuria; Adrenoleukodystrophy (ALD); Krabbe Disease; Metachromatic Leukodystrophy (MLD); Sphingolipidoses; Peroxisomal Disorders

Summary: rationale: chemotherapy administration before a donor stem cell transplant is necessary to stop the patient's immune system from rejecting the donor's stem cells. when healthy stem cells from a donor are infused into the patient, the donor white blood cells can provide the missing enzyme that causes the metabolic disease. sometimes the transplanted cells from a donor can make an immune response against the body's normal cells. giving a monoclonal antibody, alemtuzumab, before transplant and cyclosporine and mycophenolate mofetil before and after transplant may stop this from happening. this may be an effective treatment for inherited metabolic disorders. purpose: the design of this study is to achieve donor cell engraftment in patients with standard-risk inherited metabolic diseases with limited peri-transplant morbidity and mortality. this will be achieved through the administration of the chemotherapy regimen described. the intention is to follow transplanted patient for years after transplant monitoring them for complications of their disease and assisting families with a multifaceted interdisciplinary approach.

primary objective: * to estimate the proportion of patients with donor derived engraftment at day 100 post transplant as defined by 80% or greater donor cells in the cd3 (t cell) fraction secondary objectives: * to determine the incidence and severity of graft-versus-host disease (gvhd) by day 100 * to determine the incidence of peri-transplant mortality (death by day 100) * to monitor donor cell chimerism at various time points following allogeneic transplantation with this transplant regimen as determined at day 28, 42, 100, 6 months and yearly for 5 years.

Eligibility criteria:
inclusion criteria: * must have diagnosis of one of the following: mucopolysaccharidosis disorder, glycoprotein metabolic disorder, sphingolipidoses or inherited leukodystrophy, peroxisomal disorder or other inherited diseases of metabolism * must have an acceptable graft source as defined by university of minnesota criteria * adequate organ function exclusion criteria: * pregnant - menstruating females must have a negative serum pregnancy test within 14 days of treatment start * evidence of human immunodeficiency virus (hiv) infection or known hiv positive serology

Keywords: inherited metabolic disorders